Pipeline

Ifebemtinib

Ifebemtinib (also known as IN10018, ifebe, BI853520) is an orally administered, highly potent and selective small-molecule inhibitor of focal adhesion kinase (FAK). InxMed’s translational research has established FAK inhibition as a promising therapeutic strategy in the fight against cancer.

Overcoming Tumor Defense: Proof-of-Concept Achieved in Multiple Cancers

Ifebemtinib exhibits significant synergistic potential across a wide range of therapeutic modalities. Clinically, it has demonstrated synergistic efficacy in combination with chemotherapy, targeted therapies, antibody-drug conjugates, and immunotherapies. InxMed is currently conducting two registrational trialsin China, including KRAS G12C mutation NSCLC and platinum-resistant ovarian cancer along with multiple proof-of-concept studies in colorectal, melanoma, and pancreatic cancers. 

Registrational Stage with Breakthrough Potential

A Synergistic Engine for RASi and ADC Combinations

Ifebemtinib has demonstrated its significant potential as a backbone therapy in cancer treatment and have the biggest impacts via synergy with two unprecedent opportunities for cancer treatment: RASi and ADC, potentially powering toward IO therapy. Further expansions of ifebemtinib to pivotal trials in combination with RAS inhibitors and POC trials in combination with ADC are already in preparation. It has received Breakthrough Therapy Designations from the NMPA across three indications and Fast Track Designation from the FDA for one indication.

Good Safety Profile

Nearly 700 patients and healthy volunteers have received Ifebemtinib, either as monotherapy or in combination. The majority of reported adverse events (AEs) were Grade 1 or 2. Grade 3 AEs were observed with low incidence, and Grade 4 AEs were rare. No Grade 5 AEs or treatment-related deaths have been reported. Furthermore, when combined with chemotherapy, targeted therapy, or immunotherapy, ifebemtinib demonstrates a favorable and manageable safety profile without significantly increasing overall toxicity.

Good Safety Profile

Back